Transformation Time For Minoryx With Leriglitazone Filing
EMA Submission For Rare Brain Disease Drug
Executive Summary
The Spanish biotech, formed in 2011, is preparing for the potential European launch of leriglitazone for X-linked adrenoleukodystrophy after the EMA accepted its file.
You may also be interested in...
Neuraxpharm Rebrands Spanish Subsidiary As It Focuses On European Profile
Neuraxpharm has rebranded a Spanish finished dosage form facility to mark its “full integration” within the group, as it focuses on building its profile in Europe.
Bluebird’s Zynteglo Launch Under Way, But First Revenue Will Take Months
Bluebird bio will not see revenue for Zynteglo until it is infused into beta-thalassemia patients, which will take months due to the ex vivo gene therapy’s complex manufacturing and quality control process.
Scrip M&A Podcast: Which Companies Could Be Acquired Next?
The editorial team from Scrip discusses the M&A potential of various emerging biopharmas, such as Viking, Verona, Altimmune, Xenon and Crinetics.